治疗采用低甲基化药物和组蛋白去乙酰化酶抑制剂的体外基础：能否利用表观遗传学变化来监测治疗？
In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?
机构信息
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21287, USA.
出版信息
Leuk Res. 2009 Dec;33 Suppl 2(Suppl 2):S2-6. doi: 10.1016/S0145-2126(09)70226-7.
Abstract
Hematopoietic disorders such as myelodysplastic syndromes (MDS) show a high frequency of methylation of tumor suppressor genes. DNA methyltransferase (DNMT) inhibitors such as azacitidine and decitabine are used to target DNA methylation in MDS patients. Combining these drugs with histone deacetylase (HDAC) inhibitors in vitro resulted in synergistic tumor suppressor gene re-expression. Several phase I trials have examined methylation, gene expression and DNA damage as markers of clinical response to DNMT and HDAC inhibitors, with conflicting results. Trials are ongoing to investigate early methylation changes and DNA damage markers to understand the mechanisms of these drugs and as potential predictors of clinical response.
摘要
造血系统疾病如骨髓增生异常综合征（MDS）表现出肿瘤抑制基因高甲基化频率。DNA 甲基转移酶（DNMT）抑制剂，如阿扎胞苷和地西他滨，被用于靶向 MDS 患者的 DNA 甲基化。将这些药物与组蛋白去乙酰化酶（HDAC）抑制剂联合应用于体外可导致协同的肿瘤抑制基因再表达。几项 I 期临床试验已经研究了甲基化、基因表达和 DNA 损伤作为 DNMT 和 HDAC 抑制剂临床反应的标志物，结果存在矛盾。目前正在进行临床试验以研究早期甲基化变化和 DNA 损伤标志物，以了解这些药物的作用机制，并作为临床反应的潜在预测指标。
相似文献
1
In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?
Leuk Res. 2009 Dec;33 Suppl 2(Suppl 2):S2-6. doi: 10.1016/S0145-2126(09)70226-7.
2
Deacetylase inhibitors for the treatment of myelodysplastic syndromes.
Leuk Lymphoma. 2015 May;56(5):1205-12. doi: 10.3109/10428194.2014.946025. Epub 2015 Feb 24.
3
Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.
Crit Rev Oncol Hematol. 2013 Nov;88(2):231-45. doi: 10.1016/j.critrevonc.2013.06.004. Epub 2013 Jul 7.
4
Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Expert Opin Investig Drugs. 2011 Apr;20(4):465-93. doi: 10.1517/13543784.2011.559164. Epub 2011 Mar 8.
5
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Cancer. 2015 Feb 15;121(4):556-61. doi: 10.1002/cncr.29085. Epub 2014 Oct 21.
6
Epigenetic therapy for myelodysplastic syndromes has entered center stage.
Leuk Res. 2009 Dec;33 Suppl 2:S27-8. doi: 10.1016/S0145-2126(09)70231-0.
7
Epigenetic changes in the myelodysplastic syndrome.
Hematol Oncol Clin North Am. 2010 Apr;24(2):317-30. doi: 10.1016/j.hoc.2010.02.007.
8
Current status of epigenetic treatment in myelodysplastic syndromes.
Ann Hematol. 2008 Aug;87(8):601-11. doi: 10.1007/s00277-008-0477-9. Epub 2008 Apr 5.
9
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Semin Hematol. 2008 Jan;45(1):23-30. doi: 10.1053/j.seminhematol.2007.11.007.
10
Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.
Leuk Res. 2009 Dec;33 Suppl 2:S18-21. doi: 10.1016/S0145-2126(09)70229-2.
引用本文的文献
1
The inhibitory and transcriptional effects of the epigenetic repurposed drugs hydralazine and valproate in lymphoma cells.
Am J Cancer Res. 2024 Jun 15;14(6):3068-3082. doi: 10.62347/IDKG8587. eCollection 2024.
2
Low-intensity regimens standard-intensity induction strategies in acute myeloid leukemia.
Ther Adv Hematol. 2020 Mar 18;11:2040620720913010. doi: 10.1177/2040620720913010. eCollection 2020.
3
Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation.
Curr Oncol Rep. 2020 Jan 23;22(1):4. doi: 10.1007/s11912-020-0869-0.
4
SFRP1 is a possible candidate for epigenetic therapy in non-small cell lung cancer.
BMC Med Genomics. 2016 Aug 12;9 Suppl 1(Suppl 1):28. doi: 10.1186/s12920-016-0196-3.
5
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.
Arch Toxicol. 2013 Aug;87(8):1315-530. doi: 10.1007/s00204-013-1078-5. Epub 2013 Aug 23.
6
Synergetic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes.
Invest New Drugs. 2012 Aug;30(4):1715-24. doi: 10.1007/s10637-011-9659-8. Epub 2011 Mar 29.
7
Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA.
Mol Cell Biochem. 2011 Apr;350(1-2):71-80. doi: 10.1007/s11010-010-0683-3. Epub 2010 Dec 14.
8
Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
Leukemia. 2011 Feb;25(2):271-80. doi: 10.1038/leu.2010.266. Epub 2010 Nov 26.
9
Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine.
Onco Targets Ther. 2010 Sep 7;3:157-65. doi: 10.2147/ott.s5852.
本文引用的文献
1
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Blood. 2009 Oct 15;114(16):3448-58. doi: 10.1182/blood-2009-01-200519. Epub 2009 Aug 3.
2
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.
Blood. 2009 Sep 24;114(13):2764-73. doi: 10.1182/blood-2009-02-203547. Epub 2009 Jun 22.
3
Genome-wide determination of DNA methylation by Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) for the study of acute leukemias.
Methods Mol Biol. 2009;538:395-407. doi: 10.1007/978-1-59745-418-6_20.
4
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21.
5
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Int J Cancer. 2008 Jul 1;123(1):8-13. doi: 10.1002/ijc.23607.
6
Epigenetics in cancer.
N Engl J Med. 2008 Mar 13;358(11):1148-59. doi: 10.1056/NEJMra072067.
7
p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage.
Oncogene. 2008 Jun 5;27(25):3615-23. doi: 10.1038/sj.onc.1211018. Epub 2008 Jan 28.
8
DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.
Mol Cell Biol. 2008 Jan;28(2):752-71. doi: 10.1128/MCB.01799-07. Epub 2007 Nov 8.
9
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
J Clin Oncol. 2006 Aug 20;24(24):3895-903. doi: 10.1200/JCO.2005.05.4346.
10
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Blood. 2007 Jan 1;109(1):52-7. doi: 10.1182/blood-2006-05-021162. Epub 2006 Aug 1.
Zotero 插件